A5021540495- Nuclear physics research studies
- Nuclear Physics and Applications
- Nuclear reactor physics and engineering
- High-Energy Particle Collisions Research
- Quantum Chromodynamics and Particle Interactions
- Chronic Myeloid Leukemia Treatments
- Particle physics theoretical and experimental studies
- Astronomical and nuclear sciences
- Chronic Lymphocytic Leukemia Research
- Atomic and Molecular Physics
- Nuclear Materials and Properties
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- X-ray Spectroscopy and Fluorescence Analysis
- Click Chemistry and Applications
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Radioactive Decay and Measurement Techniques
- Particle accelerators and beam dynamics
- Fungal Plant Pathogen Control
- Advanced Chemical Physics Studies
- Ion-surface interactions and analysis
- Radiation Detection and Scintillator Technologies
Novartis (United States)
2022-2025
Tris Pharma (United States)
2024-2025
University of Alabama at Birmingham
2024
Charité - Universitätsmedizin Berlin
2024
Institute of Hematology & Blood Diseases Hospital
2024
Cancer Research Institute
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Jena University Hospital
2024
Institute of Genomics and Integrative Biology
2012-2024
Bristol-Myers Squibb (United States)
2023
Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP), is approved worldwide for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in phase (CML-CP) treated ≥2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients CML-CP TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40 mg twice daily or bosutinib 500 once daily. Consistent previously published primary analysis...
Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better safety fewer side effects than currently available frontline ATP-competitive tyrosine kinase inhibitors (TKIs).
The advent of high-throughput genome scale technologies has enabled us to unravel a large amount the previously unknown transcriptionally active regions genome. Recent genome-wide studies have provided annotations repertoire various classes noncoding transcripts. Long RNAs (lncRNAs) form major proportion these novel annotated transcripts, and presently known be involved in number functionally distinct biological processes. Over 18 000 transcripts are as lncRNA, encompass including intergenic...
It is shown that the nuclear shell effects on level density disappear even at medium excitation energies of order 40 MeV. Fission-fragment anisotropy data for actinide nuclei having double-humped fission barriers are to contain evidence this effect. The implication effect production superheavy pointed out.
Fission-fragment angular distributions in a number of heavy-ion-induced fusion reactions are explained on the basis that for composite systems with fission barrier heights comparable to their intrinsic temperatures, fraction events take place before fused system equilibrates fully $K$ degree freedom. A value about 8\ifmmode\times\else\texttimes\fi{}${10}^{\ensuremath{-}21}$ s is deduced characteristic time equilibration.
A new semiempirical nuclear level density formula is proposed, which takes into account the influence of shell structure on densities and excitation energy dependence effects. The ground state pairing energies enter directly this formula, involves three mass-independent parameters characterizing average single-particle near Fermi wavelength oscillations. present formulation shown not only to give a good fit experimental data neutron resonance spacings spherical nuclei, but also provide...
Fission-fragment angular distributions in reactions of $^{10}\mathrm{B}$, $^{12}\mathrm{C}$, $^{16}\mathrm{O}$${+}^{232}$Th and $^{237}\mathrm{Np}$, $^{19}\mathrm{F}$${+}^{237}$Np have been measured. While the measured anisotropies B- C-induced fission are found to be agreement with predictions standard Halpern-Strutinsky theory, they anomalously large case O- F-induced fission. Such a discontinuous behavior anisotropy respect entrance-channel mass-to-charge asymmetry provides an...
Cancer persists as a global challenge necessitating continual innovation in treatment strategies. Despite significant advancements comprehending the disease, cancer remains leading cause of mortality worldwide, exerting substantial economic burdens on healthcare systems and societies. The emergence drug resistance further complicates therapeutic efficacy, underscoring urgent need for alternative approaches. Drug repurposing, characterized by utilization existing drugs novel clinical...
Prescission neutron multiplicities in fusion-fission reactions of $^{11}\mathrm{B}$${+}^{237}$Np, $^{11}\mathrm{B}$${+}^{232}$Th, $^{12}\mathrm{C}$${+}^{232}$Th, and $^{16}\mathrm{O}$${+}^{232}$Th, lying on either side the Businaro-Gallone mass asymmetry (${\mathrm{\ensuremath{\alpha}}}_{\mathrm{BG}}$), have been measured. The present data along with those available literature for compound systems spanning fissility range from 0.70 to 0.84 were analyzed a consistent manner deduce time scales...
The energy distributions of the prompt neutrons emitted along direction motion light and heavy fragments have been measured in laboratory system by time-of-flight method. A gridded ionization chamber is used to measure kinetic energies fission their directions with electric field ion chamber. photomultiplier associated detects scintillations gas passage a fragment gives zero-time pulse. fast neutron detector placed determines coincidence selected events. From system, emission spectra from...
CHD7 mutations are implicated in a majority of cases the congenital disorder, CHARGE syndrome. CHARGE, an autosomal dominant syndrome, is known to affect multiple tissues including eye, heart, ear, craniofacial nerves and skeleton genital organs. Using morpholino-antisense-oligonucleotide-based zebrafish model for we uncover complex spectrum abnormalities neural crest crest-derived cell types. We report first time, defects myelinating Schwann cells, enteric neurons pigment cells model. also...
Measurements of the energies prompt $K$ x rays emitted by fragments in spontaneous fission $^{252}\mathrm{Cf}$ have been made which give information concerning division nuclear charge fission. The kinetic pairs and coincident along direction fragment motion were recorded event event, using a multiparameter analyzer. measured two semiconductor detectors, x-ray with lithium-drifted silicon detector operated at dry-ice temperature. energy resolution as terms full width half-maximum 59.57-keV...
LBA6500 Background: We present primary results from ASC4FIRST (NCT04971226), the first study in CML comparing all current standard-of-care frontline TKIs with a novel agent, ASC, newly diagnosed pts. ASC Specifically Targets ABL Myristoyl Pocket (STAMP). Methods: Adults were randomly assigned 1:1 to receive 80 mg once daily or an IS TKI at standard label doses, stratified by ELTS risk category and prerandomization selected (PRS) (imatinib [IMA] second-generation [2G] TKIs), which was...
Using semiconductor detectors, the fragment angular distributions have been measured in cases of fission ${\mathrm{Bi}}^{209}$ and ${\mathrm{U}}^{238}$ induced by alpha particles various energies ranging from 23 to 115 MeV obtained Berkeley 88-in. variable-energy cyclotron. The center-of-mass were analyzed a least-squares fitting code obtain value ${{K}_{0}}^{2}$ corresponding saddle-point excitation energy ${{E}_{x}}^{s}$ for each bombarding energy. transmission coefficients ${T}_{l}$ mean...
The organization of structure and function cardiac chambers in vertebrates is defined by chamber-specific distinct gene expression. This peculiarity uniqueness the genetic signatures demonstrates functional resolution attributed to different heart. Altered expression chamber genes can lead individual related dysfunctions disease patho-physiologies. Information on transcriptional repertoire compartments important understand spectrum specific anomalies. We have carried out a genome wide...
Abstract Asciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP). The present final analysis of phase 1, open-label, nonrandomized trial (NCT02081378) assessed long-term safety, tolerability, and antileukemic activity asciminib in 115 patients with chronic myeloid leukemia without T315I mutation who received 10–200 mg twice daily (BID) or 80–200 once (cutoff: March 14, 2023). Median exposure duration was 5.9 (range, 0–8.4) years; 60.9%...
The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia phase (CML-CP) has led to increased longevity thus continued pursuit alternative therapies that are efficacious maximize tolerability. 24- 96-week analyses from ASCEMBL demonstrated superior efficacy, safety, tolerability asciminib compared with bosutinib later-line therapy, meeting primary key secondary objectives, respectively. With nearly 4 years follow-up, data demonstrate better...
6562 Background: For pediatric pts with Ph+ CML-CP, treatment options improved efficacy and long-term safety are needed. ASC is a first-in-class tyrosine kinase inhibitor (TKI) Specifically Targeting the ABL Myristoyl Pocket (STAMP), approved for adults CML-CP treated ≥2 prior TKIs. The phase Ib/II ASC4KIDS study (NCT04925479) aims to characterize pharmacokinetics (PK) profile of in pts. Methods: This multi-center, open-label included aged 1–<18 years (yrs) without T315I mutation, ≥1...
Up to 65% of patients with chronic myeloid leukemia (CML) who are treated imatinib do not achieve sustained deep molecular response, which is required attempt treatment-free remission. Asciminib the only approved BCR::ABL1 inhibitor that Specifically Targets ABL Myristoyl Pocket. This unique mechanism action allows asciminib be combined adenosine triphosphate–competitive tyrosine kinase inhibitors prevent resistance and enhance efficacy. The phase II ASC4MORE trial investigated strategy...